FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Palmer Pamela P						2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC [ ACRX ]									ionship of Reporting Pe all applicable) Director		ng Per	10% O	wner	
(Last) (First) (Middle) C/O ACELRX PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 02/05/2013									Officer (give title Other (specify below) below)  Chief Medical Officer					
351 GALVESTON DRIVE						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) REDWOOD CITY	) CA		94063		_									X	Form filed Form filed Person	-		-		
(City)	(Sta	te)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day							2A. Deemed Execution Date if any (Month/Day/Ye		.	Transaction Dis			Securities Acquired isposed Of (D) (Instr. nd 5)		5. Amount of Securities Beneficially Owned Following		Form (D) or Indire	ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	V	Amount	(A) or (D)	Price	Reported				(insu. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution any (Month/Da	Date, if	4. Transac Code (Ir 8)		5. Number Derivative Securities Acquired Disposed (Instr. 3, 4	(A) or of (D)	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou Securities Underl Derivative Securit and 4)		erlying	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A) (D)		Date			xpiration ate	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)				
Common Stock (Right to Buy) <sup>(1)</sup>	\$5.31	02/05/2013			A		388,137		02/0	)5/2014 <sup>(2)(3</sup>	) 02	2/04/2023	Common Stock	388,137	\$0.00	388,	137	D		

## Explanation of Responses:

- 1. Issued pursuant to the 2011 Equity Incentive Plan.
- 2. The shares subject to the option vest as follows: 25% of the shares suject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 5, 2013) and the remaining shares subject to the stock option vest on an equal monthly basis over the following 36 months.
- 3. The shares have double-trigger acceleration on a change of control.

/s/ James Welch, Attorney-infact 02/07/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.